In fiscal 2012, which ended Dec 31, 2012, Innovaro, Inc. reported revenue of $530,834, up 21.9% from the year before. It recorded a net loss of $10.0 million. Over the twelve months ended Sep 30, 2013, revenue was $527,689 and the net loss was $4.8 million.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2013
Sep 30, 2013
|
FY 2012
Dec 31, 2012
|
FY 2011
Dec 31, 2011
|
|---|---|---|---|
| Revenue |
1
-1.6%
|
1
+21.9%
|
0
|
| Research and development |
0
-43.1%
|
0
-45.0%
|
1
|
| Selling, general and administrative |
1
-32.0%
|
1
-6.5%
|
1
|
| Pretax income |
-6
-21.7%
|
-7
-6.7%
|
-6
|
| Income tax |
—
|
-1
-313.5%
|
-0
|
| Net income |
-5
+50.2%
|
-10
-116.1%
|
-5
|
| Weighted average shares, basic |
—
|
15
|
—
|
| Weighted average shares, diluted |
—
|
15
|
—
|
| Other measures | |||
| Depreciation and amortization |
0
-55.9%
|
1
-11.3%
|
1
|
| Margins | |||
| Pretax margin |
-1,181.59%
|
-1,254.14%
|
-1,432.37%
|
| Profit margin |
-917.31%
|
-1,882.31%
|
-1,061.92%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- INNI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Charlotte, NC
- SEC CIK
- 1098482
- Former names
- UTEK CORP (until Jul 12, 2010)
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Source: SEC EDGAR filings. This is company-reported data, not investment advice.